188 related articles for article (PubMed ID: 23336814)
1. The brain slice method for studying drug distribution in the CNS.
Loryan I; Fridén M; Hammarlund-Udenaes M
Fluids Barriers CNS; 2013 Jan; 10(1):6. PubMed ID: 23336814
[TBL] [Abstract][Full Text] [Related]
2. Translational CNS Steady-State Drug Disposition Model in Rats, Monkeys, and Humans for Quantitative Prediction of Brain-to-Plasma and Cerebrospinal Fluid-to-Plasma Unbound Concentration Ratios.
Sato S; Matsumiya K; Tohyama K; Kosugi Y
AAPS J; 2021 Jun; 23(4):81. PubMed ID: 34085128
[TBL] [Abstract][Full Text] [Related]
3. Distribution of lacosamide in the rat brain assessed by in vitro slice technique.
Gáll Z; Vancea S
Arch Pharm Res; 2018 Jan; 41(1):79-86. PubMed ID: 29019022
[TBL] [Abstract][Full Text] [Related]
4. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the blood-brain barrier.
Mangas-Sanjuan V; González-Álvarez I; González-Álvarez M; Casabó VG; Bermejo M
Mol Pharm; 2013 Oct; 10(10):3822-31. PubMed ID: 23977999
[TBL] [Abstract][Full Text] [Related]
5. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Fridén M; Bergström F; Wan H; Rehngren M; Ahlin G; Hammarlund-Udenaes M; Bredberg U
Drug Metab Dispos; 2011 Mar; 39(3):353-62. PubMed ID: 21149540
[TBL] [Abstract][Full Text] [Related]
6. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids.
Fridén M; Gupta A; Antonsson M; Bredberg U; Hammarlund-Udenaes M
Drug Metab Dispos; 2007 Sep; 35(9):1711-9. PubMed ID: 17591680
[TBL] [Abstract][Full Text] [Related]
7. Unbound Brain-to-Plasma Partition Coefficient, K
Loryan I; Reichel A; Feng B; Bundgaard C; Shaffer C; Kalvass C; Bednarczyk D; Morrison D; Lesuisse D; Hoppe E; Terstappen GC; Fischer H; Di L; Colclough N; Summerfield S; Buckley ST; Maurer TS; Fridén M
Pharm Res; 2022 Jul; 39(7):1321-1341. PubMed ID: 35411506
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.
Loryan I; Sinha V; Mackie C; Van Peer A; Drinkenburg W; Vermeulen A; Morrison D; Monshouwer M; Heald D; Hammarlund-Udenaes M
Pharm Res; 2014 Aug; 31(8):2203-19. PubMed ID: 24623476
[TBL] [Abstract][Full Text] [Related]
9. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
10. Accurate prediction of K
Ma Y; Jiang M; Javeria H; Tian D; Du Z
Heliyon; 2024 Jan; 10(2):e24304. PubMed ID: 38298681
[TBL] [Abstract][Full Text] [Related]
11. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system.
Fridén M; Ducrozet F; Middleton B; Antonsson M; Bredberg U; Hammarlund-Udenaes M
Drug Metab Dispos; 2009 Jun; 37(6):1226-33. PubMed ID: 19299522
[TBL] [Abstract][Full Text] [Related]
12. Revisiting atenolol as a low passive permeability marker.
Chen X; Slättengren T; de Lange ECM; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2017 Oct; 14(1):30. PubMed ID: 29089037
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel Lung Slice Methodology for Profiling of Inhaled Compounds.
Bäckström E; Lundqvist A; Boger E; Svanberg P; Ewing P; Hammarlund-Udenaes M; Fridén M
J Pharm Sci; 2016 Feb; 105(2):838-845. PubMed ID: 26178700
[TBL] [Abstract][Full Text] [Related]
14. Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach.
Iwasaki S; Kosugi Y; Zhu AZX; Nakagawa S; Sano N; Funami M; Kosaka M; Furuta A; Hirabayashi H; Amano N
Xenobiotica; 2019 Nov; 49(11):1251-1259. PubMed ID: 30516093
[TBL] [Abstract][Full Text] [Related]
15. Effect of transporter inhibition on the distribution of cefadroxil in rat brain.
Chen X; Loryan I; Payan M; Keep RF; Smith DE; Hammarlund-Udenaes M
Fluids Barriers CNS; 2014; 11(1):25. PubMed ID: 25414790
[TBL] [Abstract][Full Text] [Related]
16. On the rate and extent of drug delivery to the brain.
Hammarlund-Udenaes M; Fridén M; Syvänen S; Gupta A
Pharm Res; 2008 Aug; 25(8):1737-50. PubMed ID: 18058202
[TBL] [Abstract][Full Text] [Related]
17. Quantitative investigation of the brain-to-cerebrospinal fluid unbound drug concentration ratio under steady-state conditions in rats using a pharmacokinetic model and scaling factors for active efflux transporters.
Kodaira H; Kusuhara H; Fuse E; Ushiki J; Sugiyama Y
Drug Metab Dispos; 2014 Jun; 42(6):983-9. PubMed ID: 24644297
[TBL] [Abstract][Full Text] [Related]
18. Examining the Uptake of Central Nervous System Drugs and Candidates across the Blood-Brain Barrier.
Summerfield SG; Zhang Y; Liu H
J Pharmacol Exp Ther; 2016 Aug; 358(2):294-305. PubMed ID: 27194478
[TBL] [Abstract][Full Text] [Related]
19. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates.
Loryan I; Sinha V; Mackie C; Van Peer A; Drinkenburg WH; Vermeulen A; Heald D; Hammarlund-Udenaes M; Wassvik CM
Mol Pharm; 2015 Feb; 12(2):520-32. PubMed ID: 25496026
[TBL] [Abstract][Full Text] [Related]
20. Brain Distribution of Drugs: Pharmacokinetic Considerations.
Loryan I; Hammarlund-Udenaes M; Syvänen S
Handb Exp Pharmacol; 2022; 273():121-150. PubMed ID: 33258066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
